GEMOX

DRUG10 trials

Sponsors

Asan Medical Center, Institut du Cancer de Montpellier - Val d'Aurelle, Guangxi Medical University, Boehringer Ingelheim, Shanghai Jiao Tong University School of Medicine

Conditions

Advanced Biliary Tract CarcinomaAdvanced Primary Liver CancerAdvanced Urothelial CarcinomaCholangiocarcinoma of the Extrahepatic Bile DuctDigestive CancerGallbladder CancerHepatocellular CarcinomaIntrahepatic Cholangiocarcinoma

Phase 1

Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer

CompletedNCT02386397

Institut du Cancer de Montpellier - Val d'AurelleDigestive Cancer

Start: 2014-09-01End: 2019-12-01Updated: 2026-03-12

Phase 2

GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer

CompletedNCT01487720

Asan Medical CenterProstate Cancer

Start: 2008-10-31End: 2013-10-31Updated: 2013-12-03

Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma

Asan Medical CenterAdvanced Urothelial Carcinoma

Start: 2010-10-31Target: 80Updated: 2014-09-25

Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

WithdrawnNCT02534337

Guangxi Medical UniversityHepatocellular Carcinoma

Start: 2015-09-30End: 2017-09-30Updated: 2019-06-04

To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

CompletedNCT02624492

Boehringer IngelheimLymphoma, Large B-Cell, Diffuse

Start: 2016-01-28End: 2018-03-16Updated: 2019-06-17

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Shanghai Jiao Tong University School of MedicineCholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer

Start: 2016-07-31End: 2020-12-31Target: 152Updated: 2018-05-07

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

CompletedNCT03092895

Jiangsu HengRui Medicine Co., Ltd.Advanced Biliary Tract Carcinoma, Advanced Primary Liver Cancer

Start: 2017-04-24End: 2021-03-31Updated: 2026-01-29

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Tianjin Medical University Cancer Institute and HospitalIntrahepatic Cholangiocarcinoma

Start: 2022-01-13End: 2025-01-13Target: 90Updated: 2022-02-23

Evaluating the Effectiveness of Decitabine With Gemcitabine, Oxaliplatin for Relapsed/Refractory Peripheral T-cell Lymphoma

TerminatedNCT06941688

Seoul National University HospitalPeripheral T-cell Lymphoma (PTCL)

Start: 2020-11-13End: 2024-12-30Updated: 2025-04-24

Golidocitinib Combined With GemOx in RR PTCL

Not yet recruitingNCT07279584

Ruijin HospitalPeripheral T-cell Lymphomas (PTCL)

Start: 2025-12-20End: 2027-12-31Target: 31Updated: 2025-12-12

Related Papers

Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study

The Oncologist2025-06-01

Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial

International Journal of Cancer2021-07-2647 citations

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.

2021-05-0324 citations

Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

Journal for ImmunoTherapy of Cancer2021-03-0169 citations

A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

Investigational New Drugs2021-02-017 citations

Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16).

2019-10-2411 citations

A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.

Journal of Clinical Oncology2019-05-2068 citations

Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin unfit patients with advanced urothelial carcinoma: A randomized phase II study (COACH, KCSG GU10-16).

Journal of Clinical Oncology2019-05-201 citations

Gemcitabine-<i>c</i>arboplatin (GCb) versus gemcitabine-oxaliplatin (GemOx) in cisplatin un-fit advanced urothelial <i>c</i>arcinoma: Randomized phase II study (COACH Study).

Journal of Clinical Oncology2019-03-011 citations

A multicenter phase Ib-IIR trial assessing the activity of regorafenib combined with modified gemcitabine: Oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer (aBTC).

Journal of Clinical Oncology2018-05-203 citations

A multicenter phase ib-IIR trial assessing activity of regorafenib in combination with modified gemcitabine-oxaliplatin (mGEMOX) in patients with advanced biliary tract cancer (aBTC).

Journal of Clinical Oncology2018-02-016 citations